Yoshiya Tanaka
0000-0002-0807-7139
18 papers found
Refreshing results…
Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance
The management of women of childbearing age with rheumatoid arthritis: an expert report
A cross-trait genetic correlation study identified eight diseases and traits associated with psoriasis
Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long‐Term Clinical Outcomes: A Five‐Year Prospective Study
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea
Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID‐19 pandemic
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance
Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
Missing publications? Search for publications with a matching author name.